Incyte Corporation (INCY)

[TREND1]

THE CHARTIST follows this stock.

[TREND1]

Inst % Owned = 95%

[TREND1]

INCY W

[stocktrademan]

$INCY DD Notes ~ http://www.ddnotesmaker.com/INCY

bullish

$INCY recent news/filings

## source: finance.yahoo.com

Wed, 10 Dec 2014 21:20:03 GMT ~ Incyte (INCY) Gains on Positive Baricitinib Study Results


read full: http://finance.yahoo.com/news/incyte-incy-gains-positive-baricitinib-212003808.html
*********************************************************

Tue, 09 Dec 2014 13:17:36 GMT ~ Lilly, Incyte Arthritis Drug Meets Endpoint


read full: http://online.wsj.com/articles/eli-lilly-incyte-arthritis-drug-meets-endpoint-in-late-stage-trial-1418131055?mod=yahoo_hs
*********************************************************

Tue, 09 Dec 2014 12:20:03 GMT ~ Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis

[at noodls] - FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS Dec 9, 2014 7:00am INDIANAPOLIS , Dec. 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that ...

read full: http://www.noodls.com/view/613DE938D937D5C64D8868977EE0482120E10BD3
*********************************************************

Tue, 09 Dec 2014 12:05:35 GMT ~ Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis

[at noodls] - INDIANAPOLIS, Dec. 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib ...

read full: http://www.noodls.com/view/D8EE105D7A503800D0237590EA6212D79B009F1D
*********************************************************

Tue, 09 Dec 2014 12:00:00 GMT ~ Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis

[PR Newswire] - INDIANAPOLIS, Dec. 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib ...

read full: http://finance.yahoo.com/news/lilly-incyte-announce-positive-top-120000665.html
*********************************************************


$INCY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$INCY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/INCY/company-info
Ticker: $INCY
OTC Market Place: Not Available
CIK code: 0000879169
Company name: Incyte Corp.
Company website: http://www.incyte.com
Incorporated In: DE, USA


$INCY share structure

## source: otcmarkets.com

Market Value: $12,826,065,783 a/o Dec 11, 2014
Shares Outstanding: 168,941,857 a/o Oct 23, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$INCY extra dd links

Company name: Incyte Corp.
Company website: http://www.incyte.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/INCY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/INCY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=INCY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=INCY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=INCY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/news - http://finance.yahoo.com/q/h?s=INCY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/INCY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/INCY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/INCY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/INCY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=INCY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/INCY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Incyte+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Incyte+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Incyte+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.incyte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.incyte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.incyte.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/INCY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/INCY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/INCY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/INCY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/INCY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000879169&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/INCY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/INCY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=INCY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=INCY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=INCY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=INCY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=INCY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=INCY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=INCY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/INCY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=INCY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/INCY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=INCY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/INCY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/INCY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/INCY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/INCY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/INCY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/INCY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=INCY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=INCY



$INCY DD Notes ~ http://www.ddnotesmaker.com/INCY

[stocktrademan]

$INCY DD Notes ~ http://www.ddnotesmaker.com/INCY

bullish very long term
elliott wave 4 complete

$INCY recent news/filings

## source: finance.yahoo.com

Mon, 27 Oct 2014 21:04:50 GMT ~ Today's Market Thorns, Roses, and All Time Highs...


read full: http://finance.yahoo.com/tumblr/blog-todays-market-thorns-roses-and-all-time-highs-210452304.html
*********************************************************

Thu, 23 Oct 2014 12:53:12 GMT ~ Incyte to Present at the Nomura BioPharma Conference

[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 23, 2014-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the Nomura BioPharma Conference on Thursday, November 6, 2014 at 1:15 p.m. (EST) in ...

read full: http://www.noodls.com/view/3F950F018C507D0713556A4601E998D1C422BA30
*********************************************************

Thu, 23 Oct 2014 12:00:00 GMT ~ Incyte to Present at the Nomura BioPharma Conference

[Business Wire] - Incyte Corporation announced today it will present at the Nomura BioPharma Conference on Thursday, November 6, 2014 at 1:15 p.m. in Boston.

read full: http://finance.yahoo.com/news/incyte-present-nomura-biopharma-conference-120000170.html
*********************************************************

Mon, 20 Oct 2014 10:01:00 GMT ~ INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/141020/incy8-k.html
*********************************************************

Fri, 17 Oct 2014 19:01:57 GMT ~ CFO Moves: Incyte, Kosmos Energy


read full: http://blogs.wsj.com/cfo/2014/10/17/cfo-moves-incyte-kosmos-energy/?mod=yahoo_hs
*********************************************************


$INCY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$INCY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/INCY/company-info
Ticker: $INCY
OTC Market Place: Not Available
CIK code: 0000879169
Company name: Incyte Corp.
Company website: http://www.incyte.com
Incorporated In: DE, USA


$INCY share structure

## source: otcmarkets.com

Market Value: $9,799,890,963 a/o Oct 28, 2014
Shares Outstanding: 168,411,943 a/o Jul 24, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$INCY extra dd links

Company name: Incyte Corp.
Company website: http://www.incyte.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/INCY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/INCY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=INCY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=INCY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=INCY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/news - http://finance.yahoo.com/q/h?s=INCY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/INCY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/INCY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/INCY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/INCY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=INCY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/INCY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Incyte+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Incyte+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Incyte+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.incyte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.incyte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.incyte.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/INCY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/INCY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/INCY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/INCY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/INCY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000879169&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/INCY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/INCY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=INCY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=INCY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=INCY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=INCY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=INCY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=INCY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=INCY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/INCY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=INCY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/INCY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=INCY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/INCY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/INCY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/INCY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/INCY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/INCY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/INCY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=INCY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=INCY



$INCY DD Notes ~ http://www.ddnotesmaker.com/INCY

[TheFinalCD]

INCY LABEL EXPANSION NEWS

[surf1944]

12:45PM Incyte: Jakafi (ruxolitinib) continues to show improved overall survival for patients with myelofibrosis in further analyses of Phase 3 data presented at 2013 ASH (INCY) 46.14 -0.45 : Co announced today that more than 35 analyses from clinical studies of Jakafi (ruxolitinib) were presented at the 2013 American Society of Hematology (ASH) Annual Meeting from Dec. 7 to 10 in New Orleans. Jakafi, an oral JAK1/JAK2 inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF). Highlights of Key Data Presented:

After a median three-year follow-up of patients in COMFORT-I, ruxolitinib treatment continued to maintain the previously reported reductions in spleen volume and improvements in quality of life measures. Overall survival favored patients originally randomized to ruxolitinib over those originally randomized to placebo (HR=0.69; 95% CI: 0.46-1.03; P=0.067). Additionally, because of the early crossover design in COMFORT-I, at the time of this analysis, patients originally randomized to placebo had been on ruxolitinib therapy a median of approximately two years, more than twice as long as their median time on placebo. Analyses were presented to show that because of the longer time these patients received Jakafi than placebo, the magnitude of the survival benefit observed may be underestimated relative to a comparison of ruxolitinib to a true placebo.
In a pooled analysis of COMFORT-I and COMFORT-II, intermediate-2-- and high-risk patients randomized to treatment with ruxolitinib had significantly prolonged survival compared to those randomized to placebo or best available therapy (HR = 0.65; 95% CI, 0.46-0.90; P = .01). Additionally, patients with high-risk myelofibrosis who were initially randomized to treatment with ruxolitinib had an estimated survival similar to patients with intermediate-2-risk myelofibrosis in the control group. Further analysis that corrects for the early crossover to ruxolitinib suggests that the survival benefit may be underestimated because patients in the placebo and best available therapy arms could cross over to receive ruxolitinib therapy. The authors also suggest that the survival benefit observed with ruxolitinib may be the result of multiple treatment effects, such as spleen volume reduction, improvement in symptoms, and improvement in nutritional status, which warrants further study.

[surf1944]

2:13AM Incyte presents positive results from proof-of-concept Phase II clinical trial of Oral JAK1 Inhibitor in patients with active rheumatoid arthritis (INCY) 39.43 : Co announces results from a 12-week, placebo-controlled, dose-escalation Phase II proof-of-concept clinical trial involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor.In this initial Phase II trial, 12 weeks of treatment with INCB39110 showed efficacy at all doses as measured by ACR 20, ACR 50, ACR 70, and DAS 28 as compared to placebo. Clinical benefit was observed as early as one week of treatment, and the highest dose tested, once-daily 600 mg, appeared to be the most effective dose.

Safety
While larger patient populations and longer term exposure are needed to fully explore the safety profile of INCB39110, at all doses evaluated in this trial, the compound was generally well-tolerated without evidence of myelosuppression or immunosuppression. Additionally, all treatment-emergent AEs were mild to moderate in intensity; there were no drug related serious adverse events, and no serious related or unrelated infections. Mean values for evaluated safety measures, including hemoglobin, neutrophil count, platelet count and lymphocyte count, remained stable and within normal range across the 12 weeks of the study.

[FreeNorth]

Incyte to Present at the Morgan Stanley Global Healthcare Conference

[mlkrborn]

Mid-stage trial promising: Up almost $9 http://www.reuters.com/article/2013/08/21/us-incyte-study-cancer-idUSBRE97K0HY20130821?feedType=RSS&feedName=globalMarketsNews&rpc=43

[surf1944]

7:00AM Incyte provides top-line results from Phase II proof-of-concept trial of ruxolitinib in patients with refractory metastatic pancreatic cancer; overall survival analysis demonstrated a hazard ratio of 0.79 and a pre-specified subgroup analysis achieved a significant benefit with a hazard ratio of 0.47 (INCY) 27.00 : Co announced top-line results of the Phase II, randomized, double-blind, placebo-controlled RECAP trial of ruxolitinib, its oral JAK1 and JAK2 inhibitor, in combination with capecitabine in patients with recurrent or treatment refractory metastatic pancreatic cancer. The hazard ratio (HR) for overall survival (OS) in the intent to treat population was 0.79 (one-sided p=0.12), and in a pre-specified subgroup analysis conducted in patients identified prospectively as most likely to benefit from JAK pathway inhibition, the HR for OS was 0.47 (one-sided p=0.005). Within this subgroup of patients, which represented 50% of the randomized population, 6 month survival in the ruxolitinib arm was 42% vs. 11% for placebo. Durable tumor responses were only observed in patients receiving ruxolitinib, and ruxolitinib treated patients achieved a significant improvement in body weight relative to placebo.

Ruxolitinib in combination with capecitabine was generally well tolerated in this study. Among patients receiving ruxolitinib plus capecitabine 12% discontinued therapy for an adverse event, compared with 20% who received capecitabine alone. The rates of new onset grade 3 anemia, thrombocytopenia or neutropenia were 16%, 2% and 0%, respectively, among patients receiving ruxolitinib plus capecitabine and were 2%, 3% and 2%, respectively, among patients receiving capecitabine alone.

[ECole]

Presentation at wells fargo

read here

[surf1944]

6:03AM Eli Lilly and Incyte (INCY) announce Baricitinib efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study in patients with Rheumatoid Arthritis; clinical improvements observed at week 24 were sustained at the end of 52 weeks (LLY) 51.78 : Co announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with active rheumatoid arthritis. Baricitinib, formerly LY3009104, is an orally available Janus kinase inhibitor being studied for use in the treatment of certain autoimmune conditions, including RA. Among patients completing the open-label extension, clinical improvements observed at week 24 were sustained at the end of 52 weeks. The long-term extension of the JADA study evaluated the efficacy and safety of baricitinib in 201 patients taking either 4 mg (n=108) or 8 mg (n=93) once daily for up to 52 weeks. Doses could be escalated to 8 mg once daily at 28 or 32 weeks at the investigator's discretion when the patient presented more than six tender and swollen joints.

Safety signals observed during the open-label extension were consistent with previously reported results of baricitinib. Among patients who remained on the 4 mg dose, treatment-emergent adverse events occurred in 57 (53 percent); serious adverse events (SAEs) in 11 (10 percent); infections in 34 (31 percent); and serious infections in four (4 percent).

This randomized, open-label, long-term extension of Phase 2b JADA study included 201 (95 percent) of the eligible 212 patients. Of the 201 patients, 184 completed 52 weeks of treatment, 15 discontinued treatment, and two patients had not yet completed the full 52 weeks of treatment. Patients received either 4 mg or 8 mg once-daily doses of baricitinib beginning at week 24 through week 52.

[surf1944]

1:40AM Incyte presents final results from a Phase I trial of INCB024360 (INCY) 22.17 : Co announces final results today from the Phase I clinical trial for its oral indoleamine dioxygenase-1 inhibitor. The key findings of the study include:

Data demonstrate that INCB024360 achieves greater than 90% inhibition of IDO1 at generally well-tolerated doses and may represent a new treatment option for advanced malignancies
Data suggest the potential for INCB024360 to be used as monotherapy or in combination with other cancer agents
The most common grade 1 or 2 adverse events were fatigue and gastrointestinal disturbances, and the most common grade 3 or 4 adverse events were abdominal pain, hypokalemia and fatigue

[WID]

Does anyone have any comments on "Coverage resumed with a SELL at Goldman" and target $17?

Thanks!

[surf1944]

7:09AM Incyte beats by $0.06, beats on revs (INCY) 21.52 : Reports Q1 (Mar) loss of $0.12 per share, $0.06 better than the Capital IQ Consensus Estimate of ($0.18); revenues rose 96.4% year/year to $71.1 mln vs the $68.16 mln consensus. The increase in total revenues from the first quarter of 2012 to the first quarter of 2013 was primarily related to increased Jakafi product revenue and $5.9 mln of Jakavi product royalties from Novartis.

Cash Position
As of March 31, 2013, cash, cash equivalents and marketable securities totaled $270.2 mln compared to $228.4 mln as of December 31, 2012.

[surf1944]

8:01AM Incyte achieves $50 mln milestone as Oral JAK1/JAK2 inhibitor Baricitinib advances into Phase III development for rheumatoid arthritis (INCY) 16.63 : Co announces it has earned a $50 mln milestone payment from Eli Lilly (LLY) based on the formal initiation of the rheumatoid arthritis Phase III program for baricitinib, Incyte's oral JAK1/JAK2 inhibitor, formerly known as INCB28050. The Phase III program is being conducted by Lilly as part of the exclusive worldwide License, Development and Commercialization Agreement for baricitinib.

[biomanbaba]

Ok surf...tell me what trashed the shares causing a dip to 17?

[surf1944]

7:05AM Incyte beats by $0.05, beats on revs (INCY) 24.92 : Reports Q2 (Jun) earnings of $0.03 per share, $0.05 better than the Capital IQ Consensus Estimate of ($0.02); revenues rose 414.9% year/year to $86.5 mln vs the $83.89 mln consensus. The Company anticipates that revenues from Jakafi net product sales will be in the range of $120 million to $135 million in 2012. This net product revenue guidance assumes the Company adopts the sell-in method for revenue recognition in the third or fourth quarter of 2012. Therefore, this guidance includes the recognition of net product deferred revenue as of the time of adoption of the sell-in method. As of June 30, 2012, net product deferred revenue was $9.0 million.

[surf1944]

8. Incyte Corporation (INCY): Focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Market cap at $3.24B. Price at $26.07. Performance over the last quarter at 29.25%. Over the last six months, insiders were net buyers of 4,585,074 shares, which represents about 3.63% of the company's 126.24M share float.

http://seekingalpha.com/article/711221-insiders-love-these-10-outperforming-healthcare-stocks?source=yahoo

[Penny Roger$]

~ Thursday! $INCY ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $INCY ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=INCY&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=INCY&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=INCY
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=INCY#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=INCY+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=INCY
Finviz: http://finviz.com/quote.ashx?t=INCY
~ BusyStock: http://busystock.com/i.php?s=INCY&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=INCY >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[Penny Roger$]

<<< $INCY Links! >>> ~ MAC's Quick DD Links without the charts.




PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/INCY


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/INCY/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/INCY/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/INCY/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/INCY/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/INCY/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/INCY/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/INCY/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/INCY/research


Google Finance Summary ~ http://www.google.com/finance?q=INCY
Google Finance News ~ http://www.google.com/finance/company_news?q=INCY
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=INCY
Google Finance Financials ~ http://www.google.com/finance?q=INCY&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=INCY
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=INCY&histperiod=weekly#


Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=INCY+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=INCY+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=INCY+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=INCY
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=INCY+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=INCY+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/INCY
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/INCY
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=INCY+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=INCY+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=INCY+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=INCY+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=INCY+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=INCY+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=INCY+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=INCY+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=INCY+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=INCY+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=INCY+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=INCY&ty=c&ta=0&p=d


Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=INCY
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=INCY
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=INCY
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=INCY
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=INCY
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=INCY&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=INCY&exchange=US


Barchart Quote ~ http://barchart.com/quotes/stocks/INCY?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/INCY
Barchart Options Quotes ~ http://barchart.com/options/stocks/INCY
Barchart Technical Chart ~ http://barchart.com/charts/stocks/INCY&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/INCY&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/INCY
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=INCY
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/INCY
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/INCY
Barchart News Headlines ~ http://barchart.com/news/stocks/INCY
Barchart Profile ~ http://barchart.com/profile//INCY
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=INCY&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=INCY&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=INCY&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=INCY&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/INCY/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/INCY/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/INCY/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/INCY/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/INCY
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/INCY/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/INCY/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/INCY/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/INCY/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/INCY/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/INCY/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=INCY&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=INCY


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=INCY


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=INCY&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=INCY
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=INCY


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=INCY&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=INCY.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=INCY®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/INCY
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/INCY/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/INCY/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/INCY/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=INCY&selected=INCY
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=INCY&selected=INCY
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/INCY/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/INCY/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/INCY/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/INCY/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/INCY/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/INCY/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/INCY/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/INCY/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/INCY/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/INCY/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/INCY/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/INCY/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/INCY/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/INCY/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=INCY&selected=INCY
NASDAQ Financials ~ http://www.nasdaq.com/symbol/INCY/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/INCY/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/INCY/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/INCY/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/INCY/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/INCY/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/INCY/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/INCY/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/INCY.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/INCY/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/INCY/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/INCY/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/INCY/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/INCY/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/INCY/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=INCY


YCharts ~ http://ycharts.com/companies/INCY
YCharts Performance ~ http://ycharts.com/companies/INCY/performance
YCharts Dashboard ~ http://ycharts.com/companies/INCY/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=INCY&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=INCY&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=INCY&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=INCY


Zacks Quote ~ http://www.zacks.com/stock/quote/INCY
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=INCY
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=INCY


Knobias ~ http://knobias.10kwizard.com/files.php?sym=INCY


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=INCY


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/INCY/HOT_TOPIC.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=INCY&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=INCY®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=INCY®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=INCY®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=INCY®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=INCY®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=INCY


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=INCY


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=INCY&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=INCY&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=INCY
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=INCY&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=INCY


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=INCY


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=INCY


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=INCY

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=INCY
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=INCY

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=INCY

Investorpoint ~ http://www.investorpoint.com/ enter "INCY" and click search.

Hotstocked ~ http://www.hotstocked.com/ enter "INCY" and click search.

Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=INCY

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=INCY

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=INCY

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=INCY

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=INCY

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "INCY" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=INCY&submit=Short+Quote%99



DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=INCY
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=INCY
Check those searches for recent INCY mentions. If INCY is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS



MACDlinks

[surf1944]

9:26AM Incyte announces EU regulatory milestone for ruxolitinib, to receive $40 mln payment from Novartis (NVS) (INCY) 18.88 : Co announced today a European Union (EU) regulatory milestone from Novartis. The milestone includes a $40 mln payment earned based on the recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency for approval of ruxolitinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. A second payment of $60 mln would be earned once Novartis achieves reimbursement and pricing approval in specific EU countries. Ruxolitinib is known as Jakafi (ruxolitinib) in the US and will be called Jakavi in Europe.

[surf1944]

5:04PM Incyte announces that Phase III studies of Jakafi (ruxolitinib) published in The New England Journal of Medicine demonstrate significant clinical benefit for patients with myelofibrosis (INCY) 16.96 -0.14 : The New England Journal of Medicine today published results from two Phase III studies (COMFORT-I and COMFORT-II) of Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor recently approved by the FDA for the treatment of intermediate or high-risk myelofibrosis (MF). These data, which were included in the New Drug Application for Jakafi submitted by Incyte, showed that the treatment significantly reduced spleen volume and improved symptoms of MF. Additionally, in an updated analysis of COMFORT-I, treatment with Jakafi was associated with improved overall survival compared to placebo.

[Penny Roger$]

~ $INCY ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $INCY ~ Earnings expected on Monday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=INCY&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=INCY&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/INCY?
~ OTC Markets: http://www.otcmarkets.com/stock/INCY/company-info
~ Google Finance: http://www.google.com/finance?q=INCY
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=INCY#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=INCY+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=INCY
Finviz: http://finviz.com/quote.ashx?t=INCY
~ BusyStock: http://busystock.com/i.php?s=INCY&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=INCY&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=INCY
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=INCY
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=INCY
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=INCY
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=INCY
~ MarketWatch: http://www.marketwatch.com/investing/stock/INCY/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=INCY
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=INCY
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=INCY&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=INCY&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=INCY&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[surf1944]

Analysis: Investors likely to wait out 2012 drug launches
ReutersReuters – 3 hours ago

By Deena Beasley

SAN FRANCISCO (Reuters) - Burned by disappointing early sales for new, high-profile biotech medicines in 2011, healthcare investors are cautious ahead of this year's expected crop of drug launches.

Not so long ago, biotech makers could practically bank on seeing their company values jump once they obtained regulatory approval to market a drug. Now, investors are more likely to wait on the sidelines, or short a stock, ahead of proof the new treatments will be a commercial success, a process that could take months.

"People are all freaked out about product launches," said ISI Group analyst Mark Schoenebaum.

Well aware of that angst, drug developers are spending far more time laying the groundwork to get paid by insurance plans and to convince doctors and patient groups of their medicines' value as they prepare for regulatory approval.

"There was a time when products got full value prior to launch. I think we have now swung back in the other direction," said John Orwin, chief executive officer at Affymax Inc (NasdaqGS:AFFX - News), which expects U.S. regulators to decide by late March whether to approve its experimental anemia drug.

Shares of Dendreon Corp (NasdaqGS:DNDN - News), maker of the novel therapeutic prostate cancer vaccine Provenge, ended last year down 83 percent from their peak in May, while Human Genome Sciences (NasdaqGS:HGSI - News) finished with a drop of 75 percent after launching Benlysta, the first new drug for lupus in more than 50 years.

Initial sales of Provenge and Benlysta failed to live up to lofty expectations, and investors are cautious ahead of early sales results for drugs launched in 2011 by companies including Incyte Corp (NasdaqGS:INCY - News), Seattle Genetics (NasdaqGS:SGEN - News) and Savient Pharmaceuticals (NasdaqGM:SVNT - News).

Even shares of Vertex Pharmaceuticals (NasdaqGS:VRTX - News), which launched hepatitis C drug Incivek last year with record-breaking sales of $420 million for its first full quarter on the market, ended the year 44 percent below their 52-week high.

The overall sector is up so far this year, and still outperforms the wider stock market. The Nasdaq Biotech Index (Nasdaq:^NBI - News) rose 12 percent in 2011, compared with a flat return for the Standard & Poor's 500 Index (SNP:^GSPC - News).

The growing challenges for new drugs -- reimbursement, regulatory issues and safety concerns -- were major topics here this week at the annual JP Morgan healthcare conference. "Sometimes there is a gap between customers' expectations and companies' expectations," said Yoshihiko Hatanaka, CEO of Astellas Pharma (:4503.T), Japan's No. 2 drugmaker. "It is critical for us to reduce that gap."

Astellas has partnered with Medivation Inc (NasdaqGM:MDVN - News) to develop prostate cancer drug MDV3100, which could win regulatory approval as soon as late 2012.

TREND AWAY FROM BIG LAUNCHES

As the market has begun to recognize that innovative drugs have unproven real-world outcomes, companies are pursuing more niche markets.

"There is a trend away from big launches," said Ulrik Schulze, global leader for biopharma R&D at Boston Consulting Group.

In the 1990s, it typically took less than two years for a new pharmaceutical to reach peak sales, he said. That time frame is widening as companies grapple with pressure from payers and a greater focus on whether a new treatment truly improves upon existing ones.

Some drugmakers are even starting to compete on the basis of price at a drug's launch, rather than expect a premium for its novelty.

Regeneron Pharmaceuticals Inc (NasdaqGS:REGN - News), which began selling its macular degeneration drug Eylea in November, said this week that sales in the first six weeks totaled $24 million to $25 million -- well above the $5 million expected by Wall Street.

Eylea competes against Roche AG's (VTX:ROG.VX - News) well-established Lucentis, but is priced slightly lower on a per-dose basis and can be given less frequently.

CEO Leonard Schleifer said Regeneron was careful ahead of its launch to lay the groundwork with retinal physicians and to set up a system for reimbursement.

"If you deliver a product that physicians, payers, and patients think is an important product, your launch will be fine," he said.

Affymax also plans to undercut the price of its biggest rival for the treatment of anemia in kidney dialysis patients -- Amgen Inc's (NasdaqGS:AMGN - News) blockbuster Epogen.

"We recognize that peginesatide has to be part of a solution to lower costs," Orwin said, referring to the Affymax drug.

Amgen CEO-elect Robert Bradway said the company expects competition from Affymax sometime this year, but still anticipates less erosion in Epogen sales relative to 2011. Sales of Epogen, which totaled $2.5 billion in 2010, have waned over the last several years amid safety concerns.

Amgen expects the Food and Drug Administration to decide in late April whether to approve its bone drug Xgeva, or denosumab, for preventing the spread of prostate cancer to the bone.

"Xgeva is the biggest opportunity for us in 2012," Bradway said.

But uptake of denosumab for osteoporosis has been gradual and some Wall Street analysts are wary of Xgeva's potential relevance in the prevention of bone cancer.

The first high-profile drug that could reach the market this year is diabetes treatment Bydureon, which is being developed by Amylin Pharmaceuticals (NasdaqGS:AMLN - News) after it recently ended a long-time diabetes partnership with Eli Lilly & Co (NYSE:LLY - News).

The latest deadline for an FDA decision on Bydureon is January 28.

Bydureon faces strong competition from similar drugs and Amylin will for the first time be responsible for launching a drug on its own.

"We think there is substantial uncertainty and think that there is somewhat more risk of sales falling short than of exceeding our estimates," Cowen and Co said in a research note to clients.

(Reporting by Deena Beasley, editing by Matthew Lewis)

[afxm]

Thanks friend ! Good Luck here....
OT: I bought some PEIX the other day, looking to sell it higher than I bought it. :)

[mlkrborn]

approval and launching are both important:
http://www.fool.com/investing/high-growth/2011/11/17/in-biotech-approvals-important-but-its-the-launch.aspx

[mlkrborn]

approved earlier.
# Monday, December 5, 10:44 AM Incyte (INCY -2.8%) trades lower after Citi cuts the shares the shares to Neutral from Buy. Citi cites limited market potential for Jakafi after conducting a survey that showed only 35% of physicians were expected to prescribe the drug to their patients. Comment! [On the Move, Healthcare]
# Wednesday, November 16, 11:29 AM Incyte (INCY) announces the FDA's approval of Jakafi, the first drug approved to specifically treat patients with the bone marrow disease myelofibrosis. Trading halted. Comment! [Healthcare]
# Thursday, October 27, 8:31 AM Incyte (INCY): Q3 EPS of -$0.42 beats by $0.03. Revenue of $16.8M (-6% Y/Y) beats by $0.3M. (PR) Comment! [Earnings, Healthcare]
source: alpha

[afxm]

Were they expecting fda approval for a drug on 12-3-11 ?

[afxm]

you bet ! Is INCY expecting news monday ?

[mlkrborn]

afxm; good u r alive & kicking!
GL
mlkr

[afxm]

MSN Money stockscouter has a rating of 8 on incy. That is really good.
http://investing.money.msn.com/investments/stock-ratings?symbol=INCY

[afxm]

Insider Felix Baker has been buying this like a madman.
http://www.insidercow.com/history/company.jsp?company=INCY&B1=SEARCH

[mlkrborn]

$13.69 with approval news:
Incyte: FDA approved Jakafi, the first drug approved to specifically treat patients with the bone marrow disease myelofibrosis. (INCY) 12.67 +0.07 : The safety and effectiveness of Jakafi was evaluated in two clinical trials with 528 patients. Patients in both trials were resistant or refractory to available myelofibrosis therapy or ineligible for allogeneic bone marrow transplantation. All patients had enlarged spleens and were in need of treatment as a result of disease-related symptoms. The treatment is being approved ahead of the drug's Dec. 3, 2011 review goal date under the Prescription Drug User Fee Act and has been designated as an orphan drug, which identifies the disease as affecting fewer than 200,000 people in the U.S.

[GrandeS]

Another FDA approval not long ago from ALRT. Health technology company. Way under radar. Should increase 200% plus over the next month.

[Chimaera]

Zecco showing a bid of 14.45

[GrandeS]

Approval has been announced by the FDA. Will be very interesting to watch the market reaction.

[Chimaera]

Trading will resume at 11:45, fingers crossed!

[GrandeS]

Jakafi Approved!

[Chimaera]

Word is approval. Feel like I'm talking to myself here though...

[Chimaera]

INCY halted, news pending.

[Chimaera]

Hoping for a nice bounce soon...good article here for those playing through approval.

http://www.fdatracker.com/2011/11/07/incy-incytes-ruxolitinib-a-sure-thing/

[Knibio]

I believe that Incyte will go down with Tuxo on FDA approval because clinical data from independent well know doctor showed servious safety issue. There is also not much medical benefit of it. Please read data published in the top medical journal, NEJM on Oct, 2011. The approval chance is very slim.

In addition, their newly approved drug have been sold much less than expected.

[surf1944]

7:13AM Incyte beats by $0.01, beats on revs (INCY) 14.41 : Reports Q3 (Sep) loss of $0.42 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.43); revenues fell 0.6% year/year to $16.8 mln vs the $16.5 mln consensus. As of September 30, 2011, cash, cash equivalents and marketable securities totaled $317.0 mln compared to $424.2 mln as of December 31, 2010. Additionally, co adds that NDA for ruxolitinib as a treatment for myelofibrosis was filed and granted priority review by the FDA; PDUFA date set for December 3, 2011; Commercialization activities advance; sales force recruitment completed.

[surf1944]

Upcoming FDA Approval Decision Dates for Q4 2011 - How You Can Profit

http://seekingalpha.com/article/297980-upcoming-fda-approval-decision-dates-for-q4-2011-how-you-can-profit?source=yahoo

[biomanbaba]

they have a PDUFA date of 12/3 and the stock tanks? WTF

[surf1944]

7:01AM Incyte: FDA accepts NDA filing for Ruxolitinib as a treatment for Myelofibrosis (INCY) 16.24 : Co announced FDA has accepted for filing the New Drug Application for Incyte's lead investigational compound, ruxolitinib, as a potential treatment for patients with myelofibrosis. The FDA also has granted Incyte's request for Priority Review, which is given to investigational drugs that may offer either a major advance in treatment or provide a treatment where no adequate therapy exists. If the application is approved, Co anticipates that ruxolitinib could be available for US patients with MF in the fourth quarter of 2011.

[NP1986]

Incyte touted as a possible takeover target by UBS:

http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2011/06/26/bloomberg1376-LNGIR10D9L3501-02526KOF6KKV2UHGE7LS1B34NL.DTL

I don't personally see this happening, due to INCY's market cap. On the other hand, if the macro environment causes the PPS to take a beating over the next six months I think INCY could be a bargain.

Thoughts?

[mlkrborn]

INCY $17 s with research findings update:
Incyte reports additional analyses of symptomatic improvement and quality of life with Ruxolitinib in patients with myelofibrosis from the COMFORT-I study (INCY) 17.57 : Co announces additional symptom improvement and quality of life results from COMFORT-I, a randomized, double-blinded, placebo-controlled Phase III trial of Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with myelofibrosis. The data demonstrated that treatment with ruxolitinib resulted in significant reductions in spleen volume and improvements in Total Symptom Score while placebo-treated patients experienced progressive splenomegaly and worsening of symptoms. These data demonstrated that the primary endpoint of a 35% reduction in spleen volume was clearly associated with reduction of abdominal symptoms associated with an enlarged spleen. Importantly, many patients with less than 35% reduction in spleen volume also had meaningful improvement in abdominal symptoms. In addition, of patients who had a 50% or greater reduction in TSS (a key secondary endpoint), nearly 90% rated their disease as "much or very much improved" based on the PGIC scale. Also, over 50% of patients with a 25% to 50% TSS improvement rated their disease as "much or very much improved," indicating that a significant proportion of these ruxolitinib-treated patients also had meaningful improvement in their disease. Associated with these improvements were improvements in almost all sub-scales of the European Organization for Research and Treatment of Cancer Quality-of-Life 30 Questionnaire, a standard and well-validated measure of quality of life in cancer patients.